. . . well, rs, I can place my bet based on comments from you -- an anonymous nobody on a yahoo message board -- or I can follow the lead of OREX's Narachi, a former Amgen vice president, and OREX's partner Takeda Pharmaceuticals . . . it's a tough decision, but I think I'll go with the latter . . .
. . . simple, dt . . . "proprietary formulation" . . . as OREX's CEO pointed out yesterday in their news release, "Additionally, we have filed new patent applications based on Light Study data which if issued would extend NB32 intellectual property protection to 2034.". . .
. . . good luck with your self-deception, sp . . . you and e7 should get together for chocolate milk -- you could feed off each other's confirmation bias . . .
. . . repeatedly posting that drivel won't make it true, e7 . . . though I can understand your fear as an arna investor . . .
. . . SAN DIEGO, March 12, 2014 . . . "The successful interim results of the Light Study give us confidence in the prospects for NB32 approvals in the U.S., Europe, and ultimately around the globe, and we believe the study creates value in addition to providing support for regulatory decisions," said Michael Narachi, CEO of Orexigen. "The cardiovascular safety data make possible near-term lifecycle opportunities including the potential development of NB32 as a treatment for diabetes and in fixed dose combinations with other approved diabetes drugs. Additionally, we have filed new patent applications based on Light Study data which if issued would extend NB32 intellectual property protection to 2034." . . .
. . . so, rs, how was OREX able to complete even a single, small trial with such HORRIFIC, DANGEROUS, NAUSEATING, SICKENING, PAINFUL side effects? . . .
. . . functionally cure just one patient with a hopeless, monogenic disease, and I think SGMO could be a $10B market cap company virtually overnight . . . Huntington's disease, which I think they're working on with Shire, would be my pick, as most mature Americans know the Woodie Guthrie story. . . any advance against that dread disease would likely put SGMO's story on every national news program . . . and the cool thing is, news like that won't be tied to some anticipated phase 3 testing -- it could simply come out of the blue as a late-breaking data presentation at some academic meeting . . . can you image the shorts' panic then? . . .
. . . why sell? . . . well, as any ceo would know, to de-risk the investment, if that's the prudent thing to do . . . and, yes, I owned medarex for a short time -- bought in near its share-price nadir and rolled every cent of that $16 a share buyout into more bmy -- for the share-price appreciation and strong dividend . . . so what percent of your original regn investment are you still holding? . . .
. . . all you need to understand, sunshine, is that -- from all appearances -- you're on the wrong side of this trade . . . good luck . . .